SEC Comment Letter 0000000000-24-013248 to CDT Equity Inc. (CDT)
CDT Equity Inc.
Date: Dec. 2, 2024 · CIK: 0001896212 · Accession: 0000000000-24-013248
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283449
Letter
December 2, 2024 David Tapolczay Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, FL 34103 Re:Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed November 25, 2024 File No. 333-283449 Dear David Tapolczay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Todd Mason, Esq.
Show Raw Text
December 2, 2024
David Tapolczay
Chief Executive Officer
Conduit Pharmaceuticals Inc.
4581 Tamiami Trail North, Suite 200
Naples, FL 34103
Re:Conduit Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed November 25, 2024
File No. 333-283449
Dear David Tapolczay:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Todd Mason, Esq.